Compare Bank of Nova Scotia (BNS) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Ginkgo Bioworks Holdings Inc — how do they compare? Bank of Nova Scotia trades at $89.57 (market cap $108.17B), while Ginkgo Bioworks Holdings Inc trades at $9.07 (market cap $590.53M). The key difference: Bank of Nova Scotia is far larger — about 183.2× Ginkgo Bioworks Holdings Inc's market cap, and Bank of Nova Scotia pays a 3.61% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BNS | DNA | |
|---|---|---|
Market Cap | $108.17B | $590.53M |
Sector | Financials | Health |
52-Week High | $88.99 | $16.14 |
52-Week Low | $54.50 | $5.48 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.00, up 0.47% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 earnings beating expectations, revenue growth to $37.1B, and a healthy 24.86% net income margin. Recent acquisition of MapleMark Bank supports strategic growth initiatives while the dividend increase to $1.14 signals management confidence.
BNS presents a compelling investment case with consistent earnings beats, attractive dividend yield, and strategic expansion. However, elevated valuation multiples and macroeconomic sensitivity in the banking sector warrant caution. Analyst consensus remains positive with 53% buy ratings, though the stock trades near resistance levels requiring careful entry timing.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
